NDA 022068 · Novartis
Tasigna
Nilotinib Hydrochloride · Oral
NovelAccelerated approvalOrphanLast checked: Nov 20, 2026Latest source record: Aug 14, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Oct 29, 2007
Approved uses
11
Original approval plus efficacy supplements
Registered trials
185
34 Phase 3, 10 recruiting
FAERS reports
29,425
21,731 serious, 5,641 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: QT PROLONGATION and SUDDEN DEATHS Tasigna prolongs the QT interval. Prior to Tasigna administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies [see Warnings and Precautions (5.2)] . Obtain ECGs to monitor the QTc at baseline, seven days after initiation, and periodically thereafter, and following any dose adjustments [see Warnings and Precautions (5.2, 5.3, 5.7, 5.12)] . Sudden deaths have been reported in patients receiving Tasigna [see Warnings and Precautions (5.3)] . Do not administer Tasigna to patients with hypokalemia, hypomagnesemia, or long QT syndrome [see Contraindications (4), Warnings and Precautions (5.2)] . Avoid use of concomitant drugs known to prolong the QT interval and strong CYP3A4 inhibitors [see Drug Interactions (7.1, 7.2)] . Avoid food 2 hours before and 1 hour after taking the dose [see Dosage and...
What it is approved for
From the label in effect Dec 16, 2025.
Tasigna is a kinase inhibitor indicated for the treatment of: Adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. ( 1.2 ) Pediatric patients greater than or equal to 1 year of age with Ph+ CML-CP and CML-AP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy. ( 1.3 ) 1.1 Adult and Pediatric Patients With Newly Diagnosed Ph+ CML-CP Tasigna is indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Adult Patients With Resistant or Intolerant Ph+ CML-CP and CML-AP Tasigna is indicated for the treatment of adult patients with chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) resistant or intolerant to prior therapy that included imatinib. 1.3 Pediatric Patients With Resistant or Intolerant Ph+ CML-CP and CML-AP Tasigna is indicated for the treatment of pediatric patients greater than or equal to 1 year of age with chronic phase and accelerated phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy.
Mechanism: Nilotinib is an inhibitor of the BCR-ABL kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of ABL protein. In vitro, nilotinib inhibited BCR-ABL mediated proliferation of murine leukemic cell lines and human cell lines derived from patients with Ph+ CML. Under the conditions of the assays, nilotinib was able to overcome imatinib resistance resulting from BCR-ABL kinase mutations, in 32 out of 33 mutations tested. Nilotinib inhibited the autophosphorylation of the following kinases at IC50 values as indicated: BCR-ABL (20 to 60 nM), PDGFR (69 nM), c-KIT...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 23, 2021 Supplement 35 · Efficacy · priority review LabelLetter
- Sep 23, 2021 Supplement 36 · Efficacy · priority review LabelMedication GuideLetter
- Mar 22, 2018 Supplement 27 · Efficacy · priority review OrphanLabelLetterPediatric Medical Review
- Dec 22, 2017 Supplement 26 · Efficacy · priority review OrphanLabelLetter
- Jan 27, 2015 Supplement 20 · Efficacy OrphanLabelLetter
- Jan 22, 2014 Supplement 17 · Efficacy OrphanLabelLetter
- Dec 20, 2012 Supplement 11 · Efficacy LetterLabel
- Nov 18, 2011 Supplement 8 · Efficacy LabelLetter
- Jan 14, 2011 Supplement 6 · Efficacy LabelLetter
- Jun 17, 2010 Supplement 5 · Efficacy · priority review Accelerated approvalLetterLabel
- Oct 29, 2007 Original approval · Type 1 - New Molecular Entity NovelAccelerated approvalOrphanSummary ReviewPediatric Written RequestLetter
3 products under this application
- TASIGNA · NILOTINIB HYDROCHLORIDE EQ 150MG BASE · CAPSULE, ORAL · Prescription · TE AB
- TASIGNA · NILOTINIB HYDROCHLORIDE EQ 50MG BASE · CAPSULE, ORAL · Prescription · TE AB
- TASIGNA · NILOTINIB HYDROCHLORIDE EQ 200MG BASE · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Nilotinib" as an intervention, any sponsor and status, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05564377 · 2,900 participants (planned) · Start Apr 7, 2023 · Primary completion Jul 1, 2030
Drug: Alpelisib; Binimetinib and 13 more · For: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 and 12 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 484 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
- Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's DiseasePivotal-lookingStatus unknown
KeifeRx, LLCIndustry
NCT05143528 · 1,275 participants (planned) · Start Feb 1, 2022 · Primary completion Dec 31, 2025
Drug: Nilotinib BE 84mg; Nilotinib BE 112 mg and 1 more · For: Alzheimer Disease
Novartis PharmaceuticalsNovartis (NVS)
NCT01061177 · 1,090 participants · Start May 2010 · Primary completion Jul 2014
Drug: Nilotinib · For: CML in Chronic Phase
Sites: Wels, Austria; Graz, Austria; Innsbruck, Austria · 320 sites in all
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentPivotal-lookingRecruiting
Centre Leon BerardAcademic, hospital or other
NCT02029001 · 900 participants (planned) · Start Mar 2014 · Primary completion Jan 2028
Drug: Nilotinib (400 mg BID); Everolimus (10 mg QD) and 4 more · For: Malignant Solid Neoplasms
Sites: Bordeaux, France; Lyon, France; Marseille, France · 7 sites in all
- A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00471497 · 846 participants · Start Jul 31, 2007 · Primary completion Sep 2, 2009
Drug: nilotinib; imatinib · For: Myelogenous Leukemia, Chronic
Sites: Los Angeles, California; San Diego, California; Vallejo, California · 213 sites in all
- TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER StudyPivotal-lookingCompleted
University of JenaAcademic, hospital or other
NCT01657604 · 717 participants · Start Aug 24, 2012 · Primary completion May 31, 2022
Drug: Peginterferon α2b; Nilotinib · For: Chronic Myeloid Leukemia
Sites: Brno, Czechia; Aachen, Germany; Amberg, Germany · 112 sites in all
- A Study of Nilotinib Versus Imatinib in GIST PatientsPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00785785 · 644 participants · Start Mar 2009 · Primary completion Oct 2014
Drug: Nilotinib (AMN107); imatinib (STI571) · For: Gastrointestinal Stromal Tumor (GIST)
Sites: Birmingham, Alabama; Flagstaff, Arizona; Duarte, California · 165 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death3,231
- fatigue2,112
- rash1,654
- nausea1,546
- headache1,494
- dyspnoea1,395
- pain1,344
- diarrhoea1,222
- drug ineffective1,210
- malaise1,143
- pruritus1,134
- pyrexia1,134
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 10 |
| 2008 | 254 |
| 2009 | 340 |
| 2010 | 450 |
| 2011 | 955 |
| 2012 | 1,851 |
| 2013 | 1,549 |
| 2014 | 2,183 |
| 2015 | 2,111 |
| 2016 | 2,531 |
| 2017 | 1,984 |
| 2018 | 2,275 |
| 2019 | 2,686 |
| 2020 | 2,319 |
| 2021 | 2,175 |
| 2022 | 1,821 |
| 2023 | 1,545 |
| 2024 | 1,084 |
| 2025 | 748 |
| 2026 | 554 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tasigna (Nilotinib HCl)
2024 spending
$427M
Beneficiaries
3,054
26,420 claims
Per beneficiary
$139,804
$175.29 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $339,500,199 |
| 2021 | $352,216,339 |
| 2022 | $375,995,128 |
| 2023 | $394,675,625 |
| 2024 | $426,961,765 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy.
Yeung DT, Tang C, Vidovic L, et al. · Blood 2015 · Clinical Trial, Research Support, Non-U.S. Gov't
- Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Kantarjian HM, Hughes TP, Larson RA, et al. · Leukemia 2021 · Comparative Study, Randomized Controlled Trial
- Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.
Ortolan A, Webers C, Sepriano A, et al. · Ann Rheum Dis 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Drug-associated pulmonary arterial hypertension.
McGee M, Whitehead N, Martin J, et al. · Clin Toxicol (Phila) 2018 · Systematic Review
- Systematic Review and Meta-Analysis of -New-Generation Tyrosine Kinase Inhibitors versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia.
Pan P, Wang L, Wang Y, et al. · Acta Haematol 2020 · Comparative Study, Meta-Analysis
- First line treatment with newer tyrosine kinase inhibitors in chronic myeloid leukemia associated with deep and durable molecular response - systematic review and meta-analysis.
Gurion R, Raanani P, Vidal L, et al. · Acta Oncol 2016 · Meta-Analysis, Systematic Review
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.